Justin B Echouffo Tcheugui Suzanne V Arnold ABSTRACT Background Although secondary cardiovascular prevention is a focus among patients with type diabetes T D and coronary artery disease CAD or peripheral artery disease PAD the application of guideline recommended therapy in T D patients and isolated cerebrovascular disease CeVD remains unknown Methods In a US outpatient registry T D patients with established cardiovascular disease from were categorized as isolated CeVD CeVD plus CAD or PAD or isolated CAD PAD In each group we determined the proportion with optimal secondary prevention HbA C blood pressure BP mmHg use of antithrombotics use of statins non smoking cessation counseling and use of glucose lowering medications with cardioprotective effects sodium glucose cotransporter SGLT inhibitors glucagon like peptide GLP receptor agonists thiazolidinediones TZDs Hierarchical Poisson regression was used to estimate relative rate of achieving each target across groups adjusted for age and chronic kidney disease where relevant Results Our study included T D outpatients with cardiovascular disease isolated CeVD n CeVD plus CAD PAD n isolated CAD PAD n Compared with isolated CAD PAD patients isolated CeVD patients more often had an HbA C adjusted relative risk aRR CI but less often had a BP mmHg aRR CI or were prescribed antithrombotics CI statins CI GLP agonists CI SGLT inhibitors CI and TZDs aRR CI Conclusion Among T D patients those with isolated CeVD had the lowest rates of secondary cardiovascular prevention goals attainment More focus is needed on secondary prevention in patients with CeVD Sources 